Atwater Malick LLC Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Atwater Malick LLC trimmed its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 47,715 shares of the company's stock after selling 2,437 shares during the period. Johnson & Johnson accounts for approximately 2.3% of Atwater Malick LLC's investment portfolio, making the stock its 19th biggest position. Atwater Malick LLC's holdings in Johnson & Johnson were worth $6,901,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of JNJ. Vinva Investment Management Ltd increased its position in Johnson & Johnson by 6.8% in the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock valued at $17,988,000 after acquiring an additional 7,110 shares during the period. Financial Counselors Inc. increased its holdings in Johnson & Johnson by 5.3% in the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock valued at $29,996,000 after purchasing an additional 9,309 shares during the period. Meridian Investment Counsel Inc. lifted its holdings in Johnson & Johnson by 19.6% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock worth $3,667,000 after buying an additional 3,710 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock valued at $2,858,543,000 after buying an additional 102,502 shares during the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at about $69,859,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.5 %

Shares of JNJ traded down $0.74 during trading hours on Monday, reaching $147.03. The stock had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. The firm has a 50-day simple moving average of $148.51 and a 200 day simple moving average of $156.10. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $353.99 billion, a price-to-earnings ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Wall Street Analyst Weigh In

Several brokerages recently commented on JNJ. Wolfe Research began coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 target price on the stock. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 16th. Bank of America dropped their target price on shares of Johnson & Johnson from $166.00 to $160.00 and set a "neutral" rating on the stock in a report on Friday. Royal Bank of Canada increased their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $174.29.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company's stock, valued at $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.